Toward New Transmission-Blocking Combination Therapies: Pharmacokinetics of 10-Amino-Artemisinins and 11-Aza-Artemisinin and Comparison with Dihydroartemisinin and Artemether

Daniel J. Watson, a Lizahn Laing, a Liezl Gibhard, b Ho Ning Wong, c Richard K. Haynes, c Lubbe Wiesner a

a Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
b H3D, Department of Chemistry, University of Cape Town, Cape Town, South Africa
c Centre of Excellence for Pharmaceutical Sciences, Faculty of Health Sciences, North-West University, Potchefstroom, South Africa

ABSTRACT As artemisinin combination therapies (ACTs) are compromised by resistance, we are evaluating triple combination therapies (TACTs) comprising an amino-artemisinin, a redox drug, and a third drug with a different mode of action. Thus, here we briefly review efficacy data on artemisone, artemiside, other amino-artemisinins, and 11-aza-artemisinin and conduct absorption, distribution, and metabolism and excretion (ADME) profiling in vitro and pharmacokinetic (PK) profiling in vivo via intravenous (i.v.) and oral (p.o.) administration to mice. The sulfamide derivative has a notably long murine microsomal half-life (t1/2 > 150 min), low intrinsic liver clearance and total plasma clearance rates (CLint 189.4, CLtot 32.2 ml/min/kg), and high relative bioavailability (F = 59%). Kinetics are somewhat similar for 11-aza-artemisinin (t1/2 > 150 min, CLint = 576.9, CLtot = 75.0 ml/min/kg), although bioavailability is lower (F = 14%). In contrast, artemether is rapidly metabolized to dihydroartemisinin (DHA) (t1/2 = 17.4 min) and eliminated (CLint = 855.0, CLtot = 119.7 ml/min/kg) and has low oral bioavailability (F) of 2%. While artemisone displays low t1/2 of 10 min and high CLint of 302.1, it displays a low CLtot of 42.3 ml/min/kg and moderate bioavailability (F) of 32%. Its active metabolite M1 displays a much-improved t1/2 of >150 min and a reduced CLint of 37.4 ml/min/kg. Artemiside has t1/2 of 12.4 min, CLint of 673.9, and CLtot of 129.7 ml/kg/min, likely a reflection of its surprisingly rapid metabolism to artemisone, reported here for the first time. DHA is not formed from any amino-artemisinin. Overall, the efficacy and PK data strongly support the development of selected amino-artemisinins as components of new TACTs.

KEYWORDS amino-artemisinins, pharmacokinetics, antimalarial agents, combination therapies, transmission-blocking

The efficacies of artemisinin combination therapies (ACTs) comprising one of dihydroartemisinin (DHA) 2, artemether 3, or artesunate 4 (Fig. 1) with piperazine, mefloquine, amodiaquine, lumefantrine, or other are now being degraded in the face of increasing resistance of Plasmodium falciparum to the artemisinin component (1–3). Although initially reported in the countries of the greater Mekong subregion in Southeast Asia, evolution of resistant strains in other countries is now being reported (3–5). Resistance arises via induction of ring-stage quiescence in parasite phenotypes carrying point mutations, including C580Y in the P. falciparum Kelch 13 propeller domain (PK13) (6–11). It is held that DHA, used as a drug in its own right or as the principal metabolite of artemether and artesunate, competitively binds to PPI3K, which prevents the kinase binding to PK13. This thereby inhibits ubiquitinylnation and proteasome degradation leading to cell cycle arrest and quiescence (12, 13). The problem is now compounded by decreasing efficacy of the ACT partner drug (2, 14–17). The response has been to extend the treatment regimen of the one ACT, to use two different ACTs in sequence (18, 19), or to conceptualize use of triple combination therapies.
therapy (TACT) (14, 17). In the last case, DHA-piperaquine used with mefloquine or artemether-lumefantrine with amodiaquine in clinical trials indeed resulted in enhanced efficacy; for the DHA-piperaquine-mefloquine regimen, efficacy was improved from 48% for the ACT to 98% for the TACT (20). However, use of such TACTs (as is the case with current ACTs) involving the current clinical artemisinins combined with known drugs without any regard to intrinsic mechanism (21) or pharmacodynamic or pharmacokinetic aspects also carries the risk of amplifying resistance (22, 23). Also, mass drug administration (MDA) programs using ACTs to clear subclinical reservoirs of resistant parasites in Southeast Asia are under way. Thus, administration of 3-day courses of DHA-piperaquine plus single dose primaquine each month for 3 months to village populations in Cambodia is being carried out (24, 25). The practice has been criticized on ethical grounds, ambiguity in definition of subclinical parasites, and use of substantial resources in the face of outcomes that are not easily defined (26–28). Irrespective of these issues, the abnormally protracted treatment and MDA regimens do require increased pharmacovigilance (29). Nevertheless, other control modalities, including enhanced surveillance, reliable detection and treatment of infected individuals from urban, agricultural, or remote forested areas, use of insecticide-treated bednets, vector control, etc., are enhancing progress toward the goal of achieving malaria elimination in the greater Mekong subregion (30).

The artemisinins in the current ACTs (Fig. 1) have been in use since their introduction by the Chinese in the 1970s and 1980s (31–33). These, including DHA, are inducers of their own metabolism (34–36) and elicit neurotoxicity concerns (29, 37–40). DHA is thermally unstable and in aqueous solution readily rearranges to a peroxyhemiacetal (41–45) whose formation also may intrude during preparation and storage of DHA (45). Such properties highlight the intemperance associated with development of DHA as an antimalarial drug (42, 43, 46). Overall, new therapies involving rational combinations of novel drugs are urgently required for treatment of multidrug-resistant malaria (23). To this end, we are developing combinations based on discrete consideration of mechanism of action of the components (47, 48). For the first drug, we focus on new artemisinin derivatives that have enhanced efficacies against all blood stages of the malaria parasite and ideally retain baseline activities against artemisinin-resistant strains. The rationale and data supporting use of a redox-active second drug such as methylene blue which displays synergism with the new artemisinins (47, 48) and a third drug type such as a quinolone (49) based on a distinct target are presented in detail elsewhere. The artemisinin derivatives bear an amino group attached to C-10 (44) wherein antimalarial activity is enhanced (50). Examples are given in Fig. 2; these are structurally distinct to the artemisinins of Fig. 1 bearing an oxygen-linked substituent at C-10.

The best known amino-artemisinin is artemisone 6 (Fig. 2) (51, 52). It is nonneurotoxic (51, 53) and does not induce its own metabolism (54). The principal metabolite M1 12 (Fig. 2) is formed together with other metabolites structurally related to artemisone and M1 bearing hydroxyl groups at C-5 and C-7, all of which retain antimalarial activity (51, 54). Artemisone is active against murine cerebral malaria; treatment at prescribed low dose levels were
completely curative, whereas at the same dose levels, DHA and artesunate, the latter of which is currently used for treatment of cerebral malaria, elicited no cure (55). In a phase IIa trial of patients with nonsevere malaria, artemisone was curative at one-third the dose level of artesunate (54, 56–59). With this earlier data serving as a backdrop to our current efforts, we needed to establish if other amino-artemisinins possess efficacy and drug metabolism and pharmacokinetic (DMPK) profiles superior to those of artemisone 6. Thus, we conducted efficacy screens on artemiside 5, the sulfide precursor of artemisone 6 (51, 52), on artemisone 6 itself as comparator, the 10-sulfamide 7 (51), the 10-(p-fluorophenyl)amino derivative 8 (60), the 10-(phenylpiperazine)- and 10-(p-fluorophenylpiperazine) urea derivatives 9 (47) and 10 (48), 11-aza-artemisinin 11 (61, 62), and the metabolite M1 (63) 12 (Fig. 2). Several were screened against asexual blood stages of artemisinin-resistant \textit{P. falciparum} clones ARC08-22 (4G) and PL08-009 (5C) carrying the \textit{PfK13} C580Y mutation (64) and also against liver-stage \textit{P. berghei} (Pb) sporozoites (48). The data are summarized in Tables S1 to S7 in the supplemental material.

Salient features are as follows. Artemiside, artemisone, and the arylurea possess 50% inhibitory concentration (IC$_{50}$) activities ranging from 0.85 to 1.75 nM against asexual blood stages of CQ-sensitive \textit{PfNF54} and multidrug-resistant K1 and W2 strains. The sulfamide, arylamine, and phenylurea are slightly less active against all strains (1.3 to 4.7 nM), and 11-aza-artemisinin is the least active (6.02 to 10.48 nM) (Table S2) (62). Cytotoxicity assays, including those against Chinese hamster ovary (CHO) cells, indicate that the arylamine and phenylurea (50% effective concentration [EC$_{50}$] 2.4 to 2.9 \textmu M) are more toxic than artemiside, artemisone, and the arylurea (204 to >271 \textmu M) (Table S1) (47, 48). The amino-artemisinins are active against blood-stage \textit{P. falciparum} gametocytes, with activities (IC$_{50}$) against early-stage gametocytes (EG > 90% stage I to III) ranging from 1.94 nM for artemisone to 83 nM for the phenylurea. Against late-stage gametocytes (LG > 90% stage IV and V), the sulfamide is the least active (IC$_{50}$ 419.4 nM), with activities of the other compounds ranging from 1.5 to 42.4 nM. Thus, the latter are appreciably more active than methylene blue, a known gametocytocidal agent (65), with EG IC$_{50}$ of 95 nM and LG of 143 nM (Table S3). These activities thus portend utility of the amino-artemisinins as transmission-blocking agents (47, 48). 11-Aza-artemisinin is less active with EG IC$_{50}$ of 170.4 and LG of 166.1 nM (Table S4) (62). Against liver-stage \textit{P. berghei} sporozoites, IC$_{50}$ values range from 28.3 nM for

![Diagram of amino-artemisinins](image)
### RESULTS

The data are directly compared to those of DHA and artemether. An evaluation of the arylamine 8 was also included, but preliminary PK assessment in the murine model unexpectedly indicated untoward toxicity, so it was not further examined.

Initially, the arylamine 8 was also included, but preliminary PK assessment in the murine model unexpectedly indicated untoward toxicity, so it was not further examined. We report here on the properties. This becomes important for the envisaged drug combinations (67). We expected in a mean IC\textsubscript{50} 2.4 nM (66); activity against W2 is 1.9 nM. For DHA, activities are 11.2 nM (48). Against asexual blood stages of artemisinin-resistant clones carrying the \textit{PFK13 C580Y} mutation, artemiside and artemisone (IC\textsubscript{50} W2 equal to 1.69 to 2.21 nM) are equipotent against clone ARCO8-22 (4G) (1.62 to 2.43 nM) and more active against the PLO8-009 (5C) clone (0.27 to 0.29 nM). The phenylurea is also active against the ARCO8-22 (4G) clone. DHA elicits activities of 6.41 to 6.68 nM against these clones (Table S6) (48). The retention of efficacy of artemisone against artemisinin-resistant clones is consistent with earlier results involving Cambodian \textit{P. falciparum} wild-type (WT) isolates transfected to strains CamWTC580Y (C580Y K13 mutation), Cam3.IIC580Y (C580Y K13), and Cam3.IIRev (wild-type K13 sequence), wherein it essentially retains baseline activities across all strains, as reflected in a mean IC\textsubscript{50} 2.4 nM (66); activity against W2 is 1.9 nM. For DHA, activities are 11.2 and 5.2 nM, respectively. The metabolite M1 is active against drug-sensitive and resistant strains of \textit{P. falciparum} (IC\textsubscript{50} 2.5 to 8.6 nM) but less so than artemisone (IC\textsubscript{50} 0.7 to 1.1 nM) (63). However, artemisone and M1 do induce quiescence in W2 ring-stage parasites but not in a concentration-dependent manner; cultures treated with different concentrations of these drugs reach 1% parasitemia within the same time period (63). Work is under way probing the basis of this effect and how these and other drugs to be used in the putative combinations may modulate induction of quiescence in ring-stage assays involving the resistant phenotypes or indeed kill the quiescent rings.

Overall, artemiside, artemisone, and the arylurea are the frontrunners in terms of global efficacies and relatively low toxicities in \textit{vitro}. However, expression of therapeutic efficacy depends not only on biological activity but also on pharmacokinetic (PK) properties. This becomes important for the envisaged drug combinations (67). We report here on the \textit{in vitro} absorption, distribution, metabolism, and excretion (ADME) properties and PK measurement in a murine model of the compounds of Fig. 2. Initially, the arylamine 8 was also included, but preliminary PK assessment in the murine model unexpectedly indicated untoward toxicity, so it was not further examined. The data are directly compared to those of DHA and artemether. An evaluation of the compounds to be taken forward is then presented.

### TABLE 1 Solubilities, microsomal stabilities, and plasma protein binding of the artemisinins<sup>a</sup>

| Compound         | Solubility (μM)<sup>b</sup> | Microsomal half-life t<sub>1/2</sub> (min) | Intrinsic liver clearance rate CL<sub>int</sub> (ml/min/kg) | Hepatic extraction ratio E<sub>H</sub> | Plasma protein binding f<sub>p</sub> |
|------------------|-----------------------------|------------------------------------------|--------------------------------------------------------|-------------------------------------|----------------------------------|
|                  | FaSSIF pH 2                | pH 6.5<sup>c</sup> | pH 7.4<sup>c</sup> | Mouse | Rat | Human | Mouse | Rat | Human | Mouse | Rat | Human | Mouse | Rat | Human | Mouse | Rat | Human | Mouse | Rat | Human |
| DHA 2            | <5<sup>d</sup>            | <5<sup>d</sup>   | <5<sup>d</sup>   | 135.9 | 90.0 | 51.7 | 50.2 | 34.7 | 41.5 | 0.4  | 0.4  | 0.7  | ND<sup>e</sup> |
| Artemether 3     | ND                          | ND             | ND             | 17.4  | <10  | 12.5 | 392.8 | 988.2 | 171.7 | 0.8  | 0.9  | 0.9  | 0.14 |
| Artemiside 5     | 12.4                        | <5             | <5             | 12.4  | <10  | <10 | 551.3 | 1,389.2 | 450.8 | 0.9  | 1.0  | 1.0  | 0.23 |
| Artemisone 6     | 73.7                        | 74.4           | 120.4          | <10  | <10  | <10 | 805.2 | 342.5 | 242.6 | 0.9  | 0.9  | 0.9  | 0.14 |
| Sulfamide 7      | >150<sup>f</sup>           | 11.5           | >150           | 194.9 | >150 | 150 | 41.3  | 32.9  | 5.6   | 0.3  | 0.4  | 0.2  | 0.17 |
| Phenylurea 9     | 75.6                        | <5             | <5             | 13.5  | <10  | <10 | 506.0 | 1,539.0 | 394.5 | 1.7  | 1.0  | ND  | 0.14 |
| Arylurea 10      | 10.0                        | 24.0           | 27.0           | <10  | ND   | <10 | 2,485.0 | ND  | 531.0 | 0.6  | ND  | 0.6  | 0.02 |
| 11-Aza-artemisinin 11 | >150<sup>f</sup> | 144.2<sup>g</sup> | >150           | >150 | >150 | 60.0 | 36.4  | 9.0   | ND   | 0.3  | 0.1  | ND  | 0.13 |
| M1 12           | >150<sup>f</sup>           | 57.6           | 74.5           | >150 | 28.8 | >150 | 37.4  | 108.5 | 0.3  | 0.7  | ND  | 0.25 |

*Each value was obtained as technical triplicates, n = 3; ND, not determined.

<sup>a</sup>Kinetic solubility was determined in three solutions at a concentration of 200 μM but at different pH values which represent that of the gastrointestinal tract.

<sup>b</sup>Solubility of DHA could not be determined in the buffer solutions because of decomposition.

<sup>c</sup>Plasma protein binding could not be calculated as DHA was unstable in plasma.

<sup>d</sup>11-Aza-artemisinin did not readily dissolve in DMSO, and therefore the calibration standards used in this experiment were prepared in methanol.

Artemisone to 81.3 for artemether to 105.5 nM for the arylurea (Table S5); in comparison, artemether has an IC\textsubscript{50} of >10<sup>4</sup> nM (48). Against asexual blood stages of artemisinin-resistant clones carrying the \textit{PKI3 C580Y} mutation, artemiside and artemisone (IC\textsubscript{50} W2 equal to 1.69 to 2.21 nM) are equipotent against clone ARCO8-22 (4G) (1.62 to 2.43 nM) and more active against the PLO8-009 (5C) clone (0.27 to 0.29 nM). The phenylurea is also active against the ARCO8-22 (4G) clone. DHA elicits activities of 6.41 to 6.68 nM against these clones (Table S6) (48). The retention of efficacy of artemisone against artemisinin-resistant clones is consistent with earlier results involving Cambodian \textit{P. falciparum} wild-type (WT) isolates transfected to strains CamWTC580Y (C580Y K13 mutation), Cam3.IIC580Y (C580Y K13), and Cam3.IIRev (wild-type K13 sequence), wherein it essentially retains baseline activities across all strains, as reflected in a mean IC\textsubscript{50} 2.4 nM (66); activity against W2 is 1.9 nM. For DHA, activities are 11.2 and 5.2 nM, respectively. The metabolite M1 is active against drug-sensitive and resistant strains of \textit{P. falciparum} (IC\textsubscript{50} 2.5 to 8.6 nM) but less so than artemisone (IC\textsubscript{50} 0.7 to 1.1 nM) (63). However, artemisone and M1 do induce quiescence in W2 ring-stage parasites but not in a concentration-dependent manner; cultures treated with different concentrations of these drugs reach 1% parasitemia within the same time period (63). Work is under way probing the basis of this effect and how these and other drugs to be used in the putative combinations may modulate induction of quiescence in ring-stage assays involving the resistant phenotypes or indeed kill the quiescent rings.

Overall, artemiside, artemisone, and the arylurea are the frontrunners in terms of global efficacies and relatively low toxicities in \textit{vitro}. However, expression of therapeutic efficacy depends not only on biological activity but also on pharmacokinetic (PK) properties. This becomes important for the envisaged drug combinations (67). We report here on the \textit{in vitro} absorption, distribution, metabolism, and excretion (ADME) properties and PK measurement in a murine model of the compounds of Fig. 2. Initially, the arylamine 8 was also included, but preliminary PK assessment in the murine model unexpectedly indicated untoward toxicity, so it was not further examined. The data are directly compared to those of DHA and artemether. An evaluation of the compounds to be taken forward is then presented.

### RESULTS

**ADME profiling \textit{in vitro}**. The kinetic solubilities, plasma protein binding, metabolic stability, and calculated intrinsic clearance rates and hepatic extraction ratio E\textsubscript{H} for mouse, rat, and human liver microsomes (68) are shown in Table 1.

It was not possible to measure solubility of DHA at any pH because of decomposition, as noted previously (44, 51). DHA presented high clearance rates in all three microsomal systems, and again in accord with previous observations (43), the extent of plasma protein
Pharmacokinetics of Amino-Artemisinins for New TACTs Antimicrobial Agents and Chemotherapy

binding could not be established due to decomposition. The aqueous solubility of arte-
mether was not able to be determined here but is variously recorded to be <1 mg/ml, 12.1 mg/liter at 25°C (69), 0.3 mg/ml (70), or rated as insoluble (71). It also displayed poor metabolic stability with high clearance rates with mouse (MLM), rat (RLM), and human liver microsomes (HLM). This lability coupled with its auto-induction of metabolism is already established (34, 35). The relatively lipophilic artemiside with log P of 4.97 and calculated log P (ClogP) of 3.98 (Fig. 2) has low aqueous solubility of <2 mg/liter or <5.4 μM at pH 7.2 (51). Here, the compound displayed low aqueous solubility in the FaSSIF buffer at pH 6.5 and phosphate-buffered saline (PBS) buffer at pH 7.4. This suggests that it would be absorbed poorly in the fastest state. At pH 2, the modest increase in solubility to 12.4 μM is ascribed to formation of the more polar conjugate acid, with a calculated pKa of 6.99, arising from protonation of the nitrogen atom of the thiomorpholine ring. Notably, artemiside displayed high intrinsic clearance rates and short half-lives in all three liver microsome systems, predominantly due to its facile metabolism to artemisone as described below. It displayed hepatic extraction ratios in all three systems comparable to those of artesunate, again sug-
gest ing it would be rapidly metabolized in the liver. The more polar artemisone (log P of 2.49, ClogP of 2.08, aqueous solubility at pH 7.2 of 89 mg/liter or 221.6 μM) (51) was appreci-
ably more soluble in the aqueous buffers but displayed high clearance rates and low half-
lives in all three liver microsome systems. The artemisone metabolite M1, ClogP 2.79, dis-
played solubility in the three aqueous buffers on par with that of artemisone but in notable contrast displayed greatly improved half-lives in the liver microsome systems. Interestingly, it exhibited varied metabolic stabilities in the different microsome systems, displaying a moderate clearance rate in MLM, a high clearance rate in RLM, and a very low rate in HLM. The sulfamide 7 is less polar (log P of 3.36, ClogP of 2.29) (51) than artemisone and was reported to possesses good solubility in water at pH 7.2 (294 mg/liter or 811 μM) (51). However, here, while it displayed acceptable solubility at pH 2, it exhibited poor solubility in the other aqueous buffers. It was cleared at a moderate rate by MLM and RLM, although comparatively it had an encouragingly low clearance rate in HLM, indicative of a less facile metabolism. The phenylurea 9 had improved solubility at pH 2 only but displayed very high clearance rates and low half-lives. The ary lurea 10 exhibited moderate solubility in all three aqueous buffers and was cleared rapidly in MLM and HLM. 11-Aza-artemisinin 11 displayed the best solubility of all compounds (>144.2 μM) in the three aqueous solutions; as it con-
tains no basic nitrogen atoms, this represents an intrinsic solubility. It also displayed the lowest clearance rates in all three microsome systems with a moderate clearance rate in MLM and a low rate in RLM. Notably, the half-life, clearance rate, and extraction ratio of 11-aza-
ar t e m is in 

the murine model described here (73) are included in Tables 2 and 3. It demonstrates a very long half-life, a low intrinsic clearance rate, and a relatively high bioavailability. The properties stand in stark contrast to those of the artemisinins and highlight the notably poor “drug-likeness” (74) of the latter.

The plasma concentration-time curves derived from the PK data are shown in Fig. 3 to 7. Artemether (Fig. 3) exhibited a short half-life (1.4 h) with a high intrinsic clearance rate (855.0 ml/min/kg) and a low bioavailability of 2%. DHA was rapidly formed following i.v. and p.o. dosing (Fig. 3). This underscores the lability of artemether as noted elsewhere (34, 35).

Artemisone displayed a short half-life (1.8 h) as well as a high clearance rate (673.9 ml/min/kg) and a low bioavailability of 1%. Notably, we record here for the first time that it was relatively rapidly metabolized to artemisone and subsequently into the unsaturated metabolite M1 (Fig. 4). Artemisone had the shortest half-life (0.5 h) and a high intrinsic clearance rate (302.1 ml/min/kg), which matches the calculated in vitro ADME data (Table 1). Despite this, artemisinone displayed PK parameters that were improved relative to those of the other artemisinins (Table 2). It was rapidly converted into the metabolite M1 following an oral dose of 50 mg/kg (Fig. 5) and possessed an improved bioavailability of 32%. This compares quite well with earlier data obtained following a single oral dose of artemisone at each of 3, 10, and 30 mg/kg to female rats (51, 54). Thus, peak plasma concentrations were reached between 15 and 60 min. The corresponding C_{max} and elimination half-lives were 35, 230, and

### Table 2: Pharmacokinetic parameters calculated from the intravenous administration (i.v.) of the artemisinins to male C57/BL6 mice at a dose of 10 mg/kg (n = 3)

| Compound (i.v.) | t_{max} (h) | V (liter/kg) | CL_{tot} (ml/min/kg) | CL_{int} (ml/min/kg) | AUC (min/µmol/liter) |
|----------------|-------------|-------------|----------------------|----------------------|----------------------|
| Artemether 3   | 1.4 ± 0.2   | 14.1 ± 1.3  | 119.7 ± 39.0         | 855.0                | 304.4 ± 80           |
| DHA 2 from artemether 3 | 1.8 ± 0.5   | 24.3 ± 9.3  | 155.0 ± 46.4         | 673.9                | 184.9 ± 43           |
| Artemisone 6 from artemiside 5 | 0.5 ± 0.03  | 1.9 ± 0.1   | 42.3 ± 2.1           | 302.1                | 577.5 ± 30           |
| Artemisone 6   | 0.01 ± 0.2  | 0.6 ± 0.4   | 32.2 ± 6.2           | 189.4                | 864.1 ± 213          |
| Phenylurea 9   | 1.3 ± 0.1   | 6.03 ± 0.3  | 55.9 ± 3.3           | 399.3                | 431.9 ± 27           |
| Arylurea 10    | 1.3 ± 0.3   | 6.92 ± 2.9  | 58.9 ± 3.5           | 2945.0               | 315.9 ± 33           |
| 11-Aza-artemisinin 11 | 3.1 ± 0.8   | 19.4 ± 7.5  | 75.0 ± 8.9           | 576.9                | 462.7 ± 117          |
| Tafenoquine    | 43.7 ± 1.5  | 2.34 ± 0.0  | ND                   | 1.84                 | 2.363 ± 146          |

*CL_{tot} total plasma clearance; CL_{int} intrinsic plasma clearance; V, volume of distribution during elimination phase; AUC, area under the concentration-time curve from 0 h to last; ND, not determined. Mean ± standard deviation (SD) reported.

### Table 3: Pharmacokinetic parameters calculated from the oral administration (p.o.) of the artemisinins to male C57/BL6 mice at a dose of 50 mg/kg (n = 3)

| Compound (p.o.) | T_{max} (h) | C_{max} (µM) | AUC (min/µmol/liter) | F (%) | Ratio AUC_{(p-last)} metabolite/parent |
|----------------|-------------|--------------|----------------------|-------|--------------------------------------|
| Artemether 3   | 0.1 ± 0.0   | 0.6 ± 0.2    | 32.3 ± 20            | 2 ± 0.6 | 1.9                                  |
| DHA 2 from artemether 3 | 77 ± 12     | 1.0 ± 0.9    | 9.5 ± 2.5            | 1 ± 0.2 | 9                                    |
| Artemiside 5   | 1.3 ± 0.8   | 0.8 ± 0.3    | 101.5 ± 49           | 1.4    | 0.2                                  |
| M1 12 from artemiside 5 | 0.3 ± 0.0   | 8.0 ± 0.8    | 922.7 ± 348          | 34 ± 7.5 | 0.2                                  |
| Artemisone 6   | 0.1 ± 0.1   | 2.1 ± 0.3    | 173.3 ± 51.7         | 30.4   | 36.8                                 |
| Sulfamide 7    | 0.6 ± 0.2   | 21.7 ± 1.2   | 2562.3 ± 499         | 59.3 ± 11.6 | 1.9                                  |
| Phenylurea 9   | 0.5 ± 0.0   | 1.0 ± 0.1    | 149.5 ± 5.9          | 69.0 ± 0.3 | 2.6                                  |
| Arylurea 10    | 0.5 ± 0.0   | 2.3 ± 0.3    | 276.5 ± 48.4         | 17.5 ± 3.1 | 2.6                                  |
| 11-Aza-artemisinin 11 | 0.5 ± 0.0   | 2.6 ± 0.0    | 154.9 ± 10           | 7.15 ± 0.3 | 3.1                                  |
| Tafenoquine    | 9.0 ± 1.0   | 3.06 ± 0.37  | 11368 ± 1232         | 55 ± 2 | NA                                   |

*T_{max}, maximum concentration; T_{max}, time to C_{max}; AUC (p-last), area under the concentration-time curve from 0 h to last; F, oral bioavailability; NA, not applicable. Mean ± SD reported.

*Data from reference 73.
Based on intravenous AUC data, the bioavailability of artemisone ranged from 5 to 25%, in rough agreement with that observed here. Also noted earlier was an apparent facile saturation of first pass metabolism based on 4-week toxicological studies in female rats. Importantly, the measured $t_{1/2}$ of artemisone in rats was at marked variance with the data obtained from ex vivo bioassay studies which suggest that $t_{1/2}$ in a primate model is about 2 to 3 h (51). This was also confirmed by ex vivo bioassay of human plasma samples taken during phase I studies (54). Thus, bioassay of subject plasma samples showed artemisone equivalent concentrations to be about 2.3-fold higher at $T_{\text{max}}$ than that measured by liquid chromatography-tandem mass spectrometry (LC/MS-MS) for artemisone. The discrepancy arises because the ex vivo bioassay screen measures total activity of artemisone plus the active metabolite M1 and the hydroxylated counterparts in monkey or human plasma.

The sulfamide showed a short half-life (0.6 h) following i.v. or p.o. dosing but revealed promising exposure levels with a bioavailability of 59% (Fig. 6a). It exhibited an intrinsic clearance rate (189.4 ml/min/kg) which was the lowest of the artemisinins evaluated here. 11-Aza-artemisinin (Fig. 6b) displayed the longest half-life (3.1 h) but had a high intrinsic clearance rate (576.9 ml/min/kg) and an oral bioavailability of 7%. This does not correlate with the calculated in vitro ADME data which suggest that it is notably stable with a low intrinsic clearance rate (Table 1). The phenylurea 9 (Fig. 7a) had a poor exposure, resulting in a low bioavailability of 6.9%. It also had a short half-life (1.3 h) and a high intrinsic clearance rate (399.3 ml/min/kg). Notably, the ary lurea 10 (Fig. 7b), differing from the phenylurea in possessing a fluorine atom at C-4 of the phenyl ring (Fig. 2), presented parameters similar to those of arylurea 9 in possessing a short half-life (1.3 h), a notably rapid clearance (2,945.0 ml/min/kg), and bioavailability of 17.5%.

Importantly, DHA was not detected as a metabolite of either artemiside or artemisone (the latter in accord with previously reported data [51, 54]), the sulfamide, 11-aza-artemisinin, or the phenyl and aryl ureas. The facile metabolism of artemiside to artemisone and thence the metabolite M1 is noteworthy.
The data overall highlight the problems of metabolic stability, poor solubility, and short half-lives of the artemisinins at large. In addition, a comparison with the far more stable and better absorbed tafenoquine emphasizes the lack of drug-likeness and difficulties in applying drug-design precepts to artemisinins (74, 75). However, in comparison with DHA and artemether, the amino-artemisinins do elicit more favorable properties, although within this series in particular, the differences do not enable a clear-cut decision to be made on the “best” amino-artemisinin, with several possible exceptions. Further, any “stop-go” criteria must also incorporate overall cost of production of a particular candidate and especially relative lack of toxicity coupled with efficacy against all stages of the malaria parasite.

The inability to measure the kinetic solubility of DHA or to assess the extent of plasma protein binding because of decomposition reflects its instability (43, 45, 46, 51). However, it was possible to measure clearance rates in the microsomal systems, and these were among the slowest of the artemisinins (Table 1). Artemether displayed low exposure levels as measured by AUC values (Table 3), which is likely due to rapid plasma clearance when administered intravenously. The low bioavailability of artemether (Table 3) reflects its poor absorption and limited systemic exposure. As previously recorded (34, 35), it is rapidly metabolized to DHA; indeed, the transformation is so rapid that artemether is considered a prodrug for DHA (75).

For the first amino-artemisinin artemiside, the PK data resemble those of artemether in terms of rapid plasma clearance and volumes of distribution. The exposure and bioavailability are limited by low aqueous solubility, but they are notably susceptible to microsomal biotransformation (Table 1; Fig. 4) via rapid oxidative conversion of the thiomorpholine sulfide to the sulfone of artemisone. Such a facile sulfide to sulfone biotransformation must proceed via the known sulfoxide artemisox (51) (Fig. 2). An analogous transformation has been mapped out for the anthelmintic drug albendazole incorporating a propylthio group attached to a benzimidazole. This undergoes rapid first pass metabolism via oxidation of the sulfide to the bioactive
sulfoxide and then to the sulfone (76). Likewise, metabolism of the antitrypanosomial drug fexinidazole carrying a (4-methylthio)phenoxyl group attached to a nitroimidazole proceeds via way of the corresponding sulfoxide to the sulfone, both more polar metabolites that in contrast to fexinidazole itself elicit blood concentrations above their effective therapeutic doses against the nonapicomplexan parasite Leishmania donovani (77, 78). Thus, while the "prodrug" concept may be applied here to artemiside, the drug is highly active in its own right in vitro against P. falciparum (Tables S1 and S3). Also, the AUC of artemisone generated in situ following oral dosing of artemiside was 9-fold lower than the exposure level achieved upon oral dosing of artemisone itself (Table 3). While this initially suggests that dosing of artemiside does not result in higher levels of artemisone, no account is made here for formation and biotransformation rate of the intermediate artemisox. These aspects, including efficacy data for artemisox, the ramifications for its formation during metabolism of artemiside, and overall effects on bioavailability and plasma levels, are discussed separately.

Artemisone showed PK properties superior to those of artemether. While it possesses a low elimination half-life (Table 2), it has a much higher oral bioavailability (Table 3), reflecting more efficient absorption and slower clearance. These results correlate well with the microsomal stability (Table 1). Improved absorption may be attributed to improved solubility at physiological pH. Artemisone forms the active metabolite M1 bearing unsaturation in the thiomorpholine S,S-dioxide ring. This metabolite and its hydroxylated derivatives substantially add to overall efficacy of artemisone according to ex vivo bioassays of monkey plasma (51, 54). Metabolite M1 elicits solubility in aqueous solutions at the different pH values on par with that of artemisone but, in contrast, possesses substantially greater microsomal half-lives (Table 1). Thus, in comparison to the DHA metabolite formed from artemether or artesunate, M1 is more soluble, is more stable, and possesses excellent in vitro activities against asexual blood stages of sensitive and multidrug-resistant P. falciparum (see Table S7 in the supplemental material) (63). From a chemical viewpoint, it is noted that while N-dealkylation of drugs incorporating six-membered cyclic tertiary amines appears to be the characteristic pathway for metabolism (79, 80), desaturation as observed here is decidedly less prevalent.

The sulfamide showed PK properties that were significantly improved compared to those of artemether, including greatly improved overall systemic exposure, represented by a greater $C_{max}$ and a distinctly higher bioavailability (Table 3). Interestingly, the sulfamide had a low volume of distribution and a low clearance rate, which suggest low tissue penetration. The microsomal stability assays suggest that it is not as susceptible to biotransformation as are the other compounds (Tables 2 and 3). It is noted that analogues of the sulfamide have been prepared carrying piperazine-pyridyl substituents (48), and although efficacies are marginally improved, the additional synthetic chemistry efforts cannot now be justified in the face of the accessibility of the sulfamide (51) and its relatively favorable PK profile noted here.

With respect to the phenyl and aryl ureas (Fig. 2), we prepared the latter on the basis that the p-fluorine atom would block oxidation of the phenyl ring via arene oxide formation.
during phase I metabolism, thereby rendering the compound less toxic in vivo. Strikingly, however, the arylurea is substantially less toxic in vitro against mammalian cell lines, including CHO cells, than is the phenylurea (CHO EC50 of 204 μM versus 2.4 μM; Table S1) (48). The arylurea also has solubility that is improved relative to that of the phenylurea at higher pH (Table 1), and both compounds show relatively good bioavailability compared to that of artemether, although it is inferior to that of artemisone (Table 3). The compounds, like artemisone, are rapidly absorbed, as indicated by the respective Tmax values (Table 3).

11-Aza-artemisinin displayed a short half-life following intravenous administration (Table 2), which appears to be contrary to the calculated clearance in vitro (Table 1). When administered orally, it was poorly absorbed (Table 3). The compound possesses a secondary amide group that is an efficient H-bond donor-acceptor ensemble (81). Thus, the H-bonding capacity may explain poor absorption in vivo; it may not be able to pass via passive diffusion through cell walls. 11-Aza-artemisinin is at a higher oxidation state than is DHA, so it is unable to be metabolized into DHA (82); indeed, the metabolite could not be detected here. While its greatly enhanced thermal and hydrolytic stability with respect to those of other artemisinins have been demonstrated (61), the relative stability evinced here, albeit in in vitro screens using microsomes, is encouraging. This well-known compound is prepared in one economic step from artemisinin (61, 82), but it displays relatively mediocre activity in vitro against P. falciparum.

New antimalarial compounds should meet one or more target compound profiles (TCP) in order to inhibit the malaria parasite at different stages of its life cycle and thus relieve clinical symptoms, avoid relapse, and block transmission (83). The amino-artemisinins possess potent activities in vitro against asexual blood stages of drug-sensitive and -resistant P. falciparum strains, and selected compounds display activities against transmissible gametocyte states that are superior to those of the current clinical artemisinins and indeed of methylene blue (47, 48). These thus have the potential to block transmission, the important TCP5 feature. A substantial advantage of the amino-artemisinins is that none generates DHA as a metabolite but, like the current clinical artemisinins, they do possess relatively short half-lives. The ultimate aim is to use one of these amino-artemisinins in combination with a redox-active drug and a third drug with a different mode of action, both of which possess substantially longer half-lives, in assembling new TACTs for treatment of malaria. In working toward this goal, we have already demonstrated that combinations of artemiside or artemisone with the redox drug methylene blue exert synergistic activity against transmissible-stage P. falciparum gametocytes (47). The high efficacy of methylene blue-based combinations strongly encourages further investigation into combinations involving the amino-artemisinins, redox compounds such as phenoxazines, naphthoquinones, and others, and a third drug with a different mode of action (48).

**Conclusion.** The amino-artemisinins present in vitro ADME and in vivo PK properties that are similar or improved compared to those of DHA and artemether. Although artemisone is readily metabolized to M1 as reflected in its low elimination half-life, it displays a greater bioavailability (Table 3) that likely is due to improved solubility (Table 1). Its principal metabolite M1 is also soluble, has a much greater microsomal half-life than artemisone, and is highly active against P. falciparum in vitro. Although artemiside has low aqueous solubility, its potency against all P. falciparum blood stages, its synergism with methylene blue against transmissible blood-stage parasites (47), and its metabolism to artemisone (and hence the metabolite M1) also favor its continued examination. Of the others, the sulfamide is relatively soluble and, uniquely for an artemisinin, possesses good stability and bioavailability. While the arylurea has inferior solubility and bioavailability, it is easily prepared (48), has relatively low toxicity, and is highly potent against all P. falciparum blood stages. 11-Aza-artemisinin displays good solubility and metabolic stability, but it does have lower efficacy. However, its derivatives are substantially more active against P. falciparum (61, 62) and the apicomplexan parasite Neospora caninum (84), and this aspect coupled with the favorable PK data of the parent encourages their further examination.

**MATERIALS AND METHODS**

**Ethics.** All studies and procedures were conducted with prior approval of the animal ethics committee of the University of Cape Town (approval number 013/028) in accordance with the South African
National Standards (SANS 10386:2008) for the Care and Use of Animals for Scientific Purposes (85) and guidelines from the Department of Health (86). The use of human plasma was approved by the human research ethics committee of the University of Cape Town (HREC 783/2016).

**Materials.** Preparation of the amino-artemisinins 5 to 10 and 11-aza-artemisinin 11 and assessment of purity are described elsewhere (47, 48, 51, 52, 62). The artemisone metabolite M1 12 was prepared, characterized, and purified as previously described (51). All compounds submitted for screening were ≥95% pure according to high-performance liquid chromatography (HPLC) analyses as previously described (48).

Human whole blood and human plasma were obtained from the Western Province blood transfusion services, Cape Town, South Africa. KH2PO4 and K2HPO4 were purchased from Merck (Darmstadt, Germany). Analytical-grade acetonitrile was purchased from Anatech (Johannesburg, South Africa). Analytical-grade dimethyl sulfoxide (DMSO), formic acid, carbamazepine, propranolol hydrochloride, warfarin, procain hydrochloride, and vinpocetine were obtained from Sigma-Aldrich (St. Louis, MO, USA). NADPH was purchased from Sigma-Aldrich (Steinheim, Germany). Polyethylene glycol (PEG), polypropylene glycol (PPG), and hydroxypropylmethylcellulose (HPMC) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Human, rat, and mouse liver microsomes were obtained from Xenotech (KS, USA). All other reagents were of biochemical grade. Water was purified via a Milli-Q purification system (Millipore, Bedford, MA, USA).

For kinetic solubility assays, three solutions with differing pH were prepared. Phosphate-buffered saline (PBS) was prepared by mixing KH2PO4 (0.2 g), K2HPO4 (0.115 g), NaCl (0.8 g), and KCl (0.2 mg) in purified water (100 ml). The pH was measured and adjusted using 0.05 M HCl or 0.05 M NaOH to pH 7.4. The pH 2 solution was prepared by adding HCl (37.8 μl) to purified water (100 ml). FaSSIF buffer at pH 6.5 was prepared by adding KH2PO4 (2.042 g) and KCl (3.728 g) to purified water (50 ml) and adjusting the pH to 6.5 using 0.05 M HCl or 0.05 M NaOH as required. Simulated intestinal fluid (SIF) (Biorelevant, London, UK) powder (5.6 mg) was then added to the buffer (25 ml) to complete the process. For the liquid-liquid extraction of plasma samples, a universal buffer containing the internal standard at pH 8 was utilized. The universal buffer consists of a 1:1 mixture of buffer A comprising CH3COOH (5.72 ml), H3PO4 (6.62 ml), and H3BO3 (6.183 g) in purified water (1 liter) and buffer B comprising NaOH (20 g) in purified water (1 liter).

ADME profiling in vitro. (i) Kinetic solubility. Duplicate stock solutions of each compound at a concentration of 10 mM in DMSO were prepared in a 96-well plate in PBS at pH 7.4, water at pH 2, and FaSSIF buffer at pH 6.5 to a final concentration of 200 μM (68). These three solutions mimic the pH and conditions of the gastrointestinal tract. As the FaSSIF buffer mimics the fastest state in vitro, solubility in this buffer provides a guide as to whether compounds should be dosed with or without meals (87). Calibration standards were prepared for each compound in DMSO at 11, 100, and 220 μM (68). These standards were used to produce a calibration curve required for calculation of the concentration of each compound in the test solutions. The exception was 11-aza-artemisinin, which proved to be less soluble in DMSO in initial kinetic solubility studies, but it did dissolve in the polar test solutions. The assay was repeated with calibration standards prepared in methanol, and as the standards were within acceptable ranges, the results were considered reliable. Plates were agitated on a plate shaker for 2 h (500 rpm, 22°C). Sample analysis was carried out by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis as described in "Sample analysis" below. Peak areas were integrated, and calibration curves were constructed and used to calculate the concentrations of each compound in the three buffers.

(ii) Liver microsomes. The metabolic stability assay was performed in duplicate using 96-deepwell plates. Each compound (0.4 mM) was incubated individually in mouse, rat, and pooled human liver microsomes (0.4 mg/ml) at 37°C in the presence and absence of the cofactor NADPH (1 mM). An aliquot was taken at 0, 5, 10, 30, and 60 min, and the reaction was quenched by adding 300 μl of ice-cold acetonitrile containing the internal standard carbamazepine (0.0236 μg/ml) (88). The test compounds in the supernatant were analyzed by means of LC-MS/MS as described in "Sample analysis" below. The normalized data for each sample were used to calculate the in vitro half-life, intrinsic clearance rate, and hepatic extraction ratio from the results of this assay using the following equations (88).

Equation 1. Normalized area.

\[
\text{Normalized area} = \left( \frac{\text{Peak area of sample at time point}}{\text{Peak area of internal standard}} \right)
\]  

Equation 2. Percent parent remaining.

\[
\% \text{ Parent} = \frac{\text{Normalized peak area of sample at time point}}{\text{Normalized peak area of sample at } t = 0} \times 100
\]

Equation 3. Calculated \(t_{1/2}\).

\[
t_{1/2} = -\frac{0.693}{A}
\]

where \(A\) is the slope of the ln (% parent remaining) versus time curve of the compound.

Equation 4. CLint.

\[
\text{CLint} = \left( \frac{0.693}{t_{1/2} (\text{min})} \right) \times \left( \frac{\text{Volume of incubation (μl)}}{\text{Microsomal protein (μg)}} \right)
\]
Equation 5. Hepatic extraction ratio.

\[ E_{H} = \frac{f_{a} \times C_{L,a}}{Q_{H} + f_{a} \times C_{L,a}} \]  

(iii) Plasma protein binding. Plasma protein binding was measured using an ultracentrifugation method. The assay was performed using a 96-well microtiter plate with pooled human plasma spiked with the test compound (10 mM). An aliquot was removed and quenched using ice-cold acetonitrile containing the internal standard carbamazepine (0.0236 μg/ml) and placed in the freezer. This served as the total concentration sample. After preincubation at 37°C for 1 h, duplicate aliquots of the spiked plasma were transferred to ultracentrifugation tubes and ultracentrifuged for 4 h (21,697 \times g, 37°C, Beckman Optima L-80XP). Analyte concentration of all compounds and sample types were determined by means of LC-MS/MS as described in “Sample analysis” below.

Pharmacokinetics in vivo. (i) Animals. Healthy male C57/B16 mice each weighing approximately 25 g were used. The mice maintained at the University of Cape Town animal facility were housed in 27 21 by 18 cm cages, under controlled environmental conditions at 22 ± 2°C and a 12-h light/dark cycle. Humidity was monitored and ranged between 55 and 70%. Food and water were available ad libitum. Mice were acclimatized to their environment for 7 days before experiments were initiated.

(ii) Oral drug administration. Each of theartemether, the amino-artemisinins 5 to 10, and 11-aza-artemisinin 11 (12.5 mg) was dissolved in 0.2 ml DMSO, to which 1.8 ml 0.5% (wt/vol) HPMC in water was then added. Compounds were administered orally via gavage at a dose of 50 mg/kg (n = 3). Dosing volumes were calculated based on the weight of each mouse in the respective group. The dosing volumes ranged between 160 μl and 200 μl, ensuring that the dose remained at 50 mg/kg. Blood samples for amino-artemisinins 5 to 8 and 10 were collected via tail-bleeding predose and at 0, 0.25, 0.5, 1, 2, 4, 8, and 24 h postdose. Samples were placed in 0.5 ml lithium heparin micro vials to prevent blood coagulation. Artemether and the amino-artemisinins 5 to 8 and 10 were expected to display the characteristic short half-lives of the artemisinins, and therefore it was more important to map the initial exposure over 4 h. The phenylurea 9 and the 11-aza-artemisinin 11 were predicted to have longer half-lives and were sampled over a greater time period. The samples were immediately centrifuged at 5,590 \times g for 5 min and the plasma was transferred to new microvials. The plasma samples were stored at −80°C.

(iii) Intravenous drug administration. For the intravenous formulations, each of artemether, the amino-artemisinins 5 to 10, and 11-aza-artemisinin 11 (2.5 mg) was dissolved in 1 ml DMSO/PEG/PPG (1:3:6, vol/vol). DMSO was added first, followed by PEG and then PPG. The resulting solutions in the mixture of DMSO, PEG, and PPG (1:3:6, vol/vol) were administered intravenously at a dose of 10 mg/kg (n = 3) via injection into the dorsal penile vein. Mice were anesthetized with an intraperitoneal injection of a saline ketamine/xylazine solution. This consisted of 1 ml ketamine (100 mg/ml), 0.5 ml xylazine (20 mg/ml), and 8.5 ml PBS solution to make a total volume of 10 ml. Dosage of anesthetic preparation for mice was 0.8 ml/10 g body weight; this amounts to a dose of 80 mg/kg ketamine and 10 mg/kg xylazine. The total volume of administration was dose adjusted to 10 mg/kg with an approximate volume of 80 μl according to the weight of each animal on the morning of dosing. Blood samples for the amino-artemisinins 5 to 8 and 10 were collected via tail-bleeding predose and at 0.08, 0.25, 0.5, 1, 2, and 4 h, and blood samples for the phenylurea 9 and the 11-aza-artemisinin 11 were collected at 0.08, 0.5, 1, 2, 4, 8, and 24 h postdose. Samples were all placed in 0.5 ml lithium heparin microvials to prevent blood coagulation. The samples were immediately centrifuged at 5,590 \times g for 5 min and the plasma was transferred to new microvials. The plasma samples were stored at −80°C.

Sample analysis. Concentrations of the kinetic parameters, metabolic stability, plasma stability, plasma protein binding samples, and plasma samples from murine studies were determined using quantitative LC-MS/MS assays.

Sample extraction. For sample extraction from the kinetic solubility, metabolic stability, plasma stability, and plasma protein binding studies, each compound was extracted from 200 μl of acetonitrile by adding 350 μl ethyl acetate, which contained the internal standard carbamazepine, and vortexing for 1 min followed by centrifugation at 5,590 \times g for 5 min. The organic layer was then transferred and evaporated under a gentle stream of nitrogen at room temperature for 30 min. The dried samples were reconstituted in mobile phase, and a 5 μl sample was injected for LC-MS/MS analysis. The only exception was the arylurea 10, for which no liquid-liquid extraction was conducted; instead, the 200 μl acetonitrile solution was evaporated under a gentle stream of nitrogen at room temperature. The dried sample was reconstituted in the mobile phase, and a 5 μl sample was injected for LC-MS/MS analysis. The plasma samples for each compound from the in vivo studies were extracted by mixing 350 μl ethyl acetate with 15 μl of plasma sample and 35 μl of universal buffer containing internal standard at pH 8. The samples were vortexed for 1 min and centrifuged for 5 min, and the organic layer was then transferred and evaporated under a gentle stream of nitrogen at room temperature for 30 min. The dried samples were each reconstituted in the mobile phase, and a 5 μl sample was injected for LC-MS/MS analysis.

LC-MS/MS analysis. For all the artemisinins except the ary lurea 10, gradient chromatography was performed on a Phenomenex (Torrance, CA, USA) Luna PFP(2) analytical column (100 Å, 5 μm, 2 by 50 mm) and an AB Sciex API 5500 mass spectrometer which was operated at unit resolution in the multiple reaction monitoring (MRM) mode. The HPLC method used was a gradient method with 5 mM ammonium acetate and 0.1% acetic acid in water as the aqueous phase and a mixture of acetonitrile and methanol (1:1 vol/vol) containing 5% of the aqueous phase as the organic phase (89). The ary lurea 10 was analyzed using a Phenomenex Gemini NX-C18 (5 μm, 2.1 mm by 50 mm) column with an AB Sciex 3200 QTRAP mass spectrometer operated at unit resolution in the MRM mode. The HPLC method used was a gradient method with 5 mM ammonium acetate and 0.1% acetic acid in water as the aqueous phase and a mixture of

August 2021 Volume 65 Issue 8 e00990-21  aac.asm.org 12
REFERENCES

1. World Health Organization. 2019. Geneva: world malaria report 2019.
2. Hamilton WL, Amato R, van der Pluijm RW, Jacob CG, Quang HH, Thuy-Nhien NT, Hien TT, Hongvongthong B, Chindavongsa K, Mayxay M, Huy R, Leang R, Huch C, Dyoseley L, Amarutunga C, Suon S, Fairhurst RM, Tripura R, Peto TJ, Sovann Y, Jittamala P, Hanboonkunapak B, Pukrittayakamee S, Chau NH, Imwong M, Dhorda M, Vongpromek R, Chan XS, Maude RJ, Pearson RD, Nguyen T, Rockett K, Drury E, Gönczvács S, White NJ, Day NP, Kwiatkowski DP, Dondorp AM, Miotto O. 2019. Evolution and expansion of multidrug resistant malaria in Southeast Asia: a genomic epidemiology study. Lancet Infect Dis 19:943–951. https://doi.org/10.1016/S1473-3099(19)30939-5
3. Wittmer K, Dahanal FA, Delves MJ, Yahia S, Watson OJ, Strachil U, Chwarchosn O, Sornbun B, Pukrittayakamee S, Pearson RD, Howick VM, Lawrie-ck MKH, White NJ, Dondorp AM, Okell LC, Chotivanich K, Rucker A, Baum J. 2020. Transmission of artemisinin-resistant malaria parasites to mosquitoes under antimalarial drug pressure. Antimicrob Agents Chemother 65:e00898-20. https://doi.org/10.1128/AAC.00898-20
4. MalariaGEN Plasmodium falciaparum Community Project. 2016. Genomic epidemiology of artemisinin resistant malaria. Elife 5:e08714. https://doi.org/10.7554/eLife.08714.
5. Miotto O, Sekhara M, Tachibana S-I, Yamauchi M, Pearson RD, Amato R, Gonzáles S, Mehra S, Niyiyanti R, Murtur J, spice RN, Mueller I, Ikeda M, Mor T, Hirai M, Tavul L, Hetzel MW, Laman M, Barry AE, Ringwald P, Ohashi J, Hombhanje F, Kwiatkowski DP, Mita T. 2020. Emergence of artemisinin-resistant Plasmodium falciaparum with kelch13 C580Y mutations on the island of New Guinea. PLoS Pathog 16:e1009133. https://doi.org/10.1371/journal.ppat.1009133.
6. Ariey F, Witkowski B, Amarutunga C, Beghain J, Langlois A-C, Khin N, Kim S, Duni V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Seng S, Suon S, Chaur O, Bout DM, Ménard S, Rogers WO, Gentier B, Drury E, Kwiatkowski DP, Ménard O. 2014. A molecular marker of artemisinin-resistant Plasmodium falciaparum malaria. Nature 505:50–55. https://doi.org/10.1038/nature12876.
7. Takala-Harrison S, Jacob CG, Arze C, Cummings MP, Silva JC, Dondorp AM, Fukuda MM, Hien TT, Mayxay M, Noedl H, Nosten F, Kyaw MP, Ntien NN, Imwong M, Bethell D, Se Y, Lon C, Tyner SD, Saunders DL, Ariey F, Mercereau-Pujol O, Ménard D, Newton PN, Khantavong M, Hongvongthong B, Starzengruber P, Fuehrer H-P, Svoboda P, Khan WA, phyo AP, Niyit M, Brown TS, Adams M, Pepsin CS, Bailey J, Tan CJ, Ferdig MT, Clark TG, Miotto O, Mackniss B, Kwiatkowski DP, White NJ, Ringwald P, Ploey CV. 2015. Independent emergence of artemisinin resistance mutations among Plasmodium falciaparum in Southeast Asia. J Infect Dis 211:670–679. https://doi.org/10.1093/infdis/jiu491.
8. Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, Amarutunga C, Lim P, Mead D, Oyol SA, Dhorda M, Imwong M, Woodrow C, Manske S, Stafford J, Drury E, Campo S, Amenga-Etego L, Thanh T-NN, Tran HT, Ringwald P, Bethell D, Nosten F, phyo AP, Pukrittayakamee S, Chotivanich K, Chaur CM, Ngiou C, Suon S, Sreng S, Newton RN, Mayxay M, Khantavong M, Hongvongthong B, Huy T, Ht, Ka TP, Maiz FA, Fanei CL, Onyamboko M, Mokolou OA, Jacob CG, Takala-Harrison S, Plowe CV, Day NP, Dondorp AM, Spencer CC, McVeigh G, Fairhurst RM, White NJ, Kwiatkowski DP, et al. 2015. Genetic architecture of artemisinin-resistant Plasmodium falciaparum. Nat Genet 47:226–234. https://doi.org/10.1038/ng.3189.
9. Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, Se Y, Chans S, Thiravakul M, Sia-Ngamp M, Kuntawangsan W, Arsanak M, Buathong N, Chaorattanakase S, Gopi P, Ta–Aslorn W, Chanarat N, Sundrakes S, Kongs N, Heng TK, Ngu S, Teja–Kavaddram P, Pichyangkum S, Phan SM, Phathalaburiyam S, Juliani JJJ, Meshnick SR, Chaur CM, Prom S, Lanteri CA, Lon C, Saunders DL. 2015. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis 15:683–691. https://doi.org/10.1016/S1473-3099(15)70049-6.
10. Kheang ST, Sovannaroth S, Ek S, Chy S, Chhun P, Mao S, Nguon S, Lek DS, Menard D, Kak N. 2017. Prevalence of K13 mutation and day-3 positive parasitaemia in artemisinin-resistant malaria endemic area of Cambodia: a cross-sectional study. Malar J 16:372. https://doi.org/10.1186/s12936-017-2044-4.
11. Sá JM, Kaslow SR, Krause MA, Melendez-Muniz VA, Salzman RE, Kite WA, Zhang M, Moraes Barros RR, Mu J, Han PK, Meshon JP, Figan CE, Caleon RL, Rahman RS, Gibson TJ, Amarutunga C, Nishiguchi EP, Breglio FG, Engels TM, Velmunugan S, Riekfels S, Straimer J, Güldig NF, Deng B, Liu A, Difou A, Miura K, Tullo G, Eastman RT, Chakravarty S, James ER, Urden M, Linn C, Sun LS, Sturdevant DE, Gwadz RW, Porcella SF, Long CA, Fidock DA, Thomas ML, Fay MP, Sim BKW, Hoffman SL, Adams JH, Fairhurst RM, Su X-Z, Wellemes TE. 2018. Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciaparum cross and Aotus model. Proc Natl Acad Sci U S A 115:12513–12518. https://doi.org/10.1073/pnas.1813868115.
12. Mbangue A, Bhattacharjee S, Pandharikar T, Liu H, Estiu G, Stahelin RV, Rizk SS, Nijmoh DL, Ryan Y, Chotivanich K, Nguon C, Ghorbal M, Lopez-Rubio J-J, Pflender M, Emrich S, Mohandas N, Dondorp AM, Wiest O, Haldar K. 2015. A molecular mechanism of artemisinin resistance in Plasmodium falciaparum malaria. Nature 520:683–687. https://doi.org/10.1038/nature14412.
13. Van Hook AM. 2015. Antimalarial drugs inhibit PI3P production. Sci Signal 8:118. https://doi.org/10.1126/scisignal.aaa4781.
14. Tsou M, Adams D, Ritero T, Chirn P, Lim P, Muthi S, Soocheat D, Frédéric Ariey F, Wongprichanalai C. 2009. Failure of arteunams-falcoquine combination therapy for uncomplicated Plasmodium falciaparum malaria in southern Cambodia. Malar J 8:10. https://doi.org/10.1186/1475-2875-8-10.
31. Zhang JF. 2005. A detailed chronological record of project 523 and the malaria parasite drug resistance: the game is afoot. J Infect Dis 210:335–337. https://doi.org/10.1093/infdis/jui42.

19. World Health Organization, Geneva. Global malaria programme August 2018 status report information and data. http://www.who.int/malaria/area_malaria_resistance/en/.

20. van der Pluijm RW, Tripruga R, Hoglund RM, Phyto AP, Lek D, UI Islam A, Anvikar AR, Satpathi P, et al. 2020. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet https://doi.org/10.1016/S0140-6736(20)30552-3.

21. Haynes RK, Cheu KW, Chan HW, Wong HN, Li KY, Tang MMK, Chen M-J, Guo Z-F, Guo Z-H, Sinniah K, Witte AB, Coghi P, Monti D. 2012. Interactions between artemisinins and other antimalarial drugs in relation to the co-factor model—a unifying proposal for drug action. ChemMedChem 7:2204–2226. https://doi.org/10.1002/cmdc.201203838.

23. Krishna S. 2019. Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance: the case for Malar J 13:478. https://doi.org/10.1186/s12936-017-1942-5.

24. World Health Organization, Geneva. Global malaria programme August 2020 status report information and data. http://www.who.int/malaria/area_malaria_resistance/en/.

26. Mendis K. 2019. Mass drug administration should be implemented as a co-factor model for neurodegeneration induced by antimalarial drugs of the artemisinin type. Neurotoxicology 73:69–79. https://doi.org/10.1016/j.neuro.2019.07.005.

27. von Seidlein L, Peto TJ, Landier J, Nguyen T-N, Tripura R, Phommasone K, Watson et al. Antimicrobial Agents and Chemotherapy 2014;63:784–796. https://doi.org/10.1128/AAC.02214-17.

28. Lubell Y, Aguas RJ, Maude RJ, White LJ, Nosten F. 2021. Estimating the potential benefits of mass drug administrations on falciparum malaria elimination with mass drug administrations on falciparum malaria on the Thai-Myanmar border (2003–2005) - a unifying proposal for drug action. ChemMedChem 7:2204–2226. https://doi.org/10.1002/cmdc.201203838.

29. Rosenthal PJ. 2020. Are three drugs for malaria better than two? Lancet 391:1926–1927. https://doi.org/10.1016/S0140-6736(20)30560-2.

30. Landier J, Parker DM, Thu AM, Lwin KM, Deoas G, Nosten FH, for the Malaria Elimination Task Force Group. Global effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme. Lancet 391:1916–1926. https://doi.org/10.1016/S0140-6736(18)30792-X.

31. van Seidlein L, Peto TJ, Landier J, Nguyen T-N, Tripruga R, Phommasone K, Pongvongsa T, Lwin KM, Keereecharoen L, Kajeechiwa L, Thwin MM, Da DD, Haynes RK. 2018. Accessible and distinct decoquinate and apicomin parasites. Front Chem 7:901. https://doi.org/10.3389/fchem.2019.00067.

32. Guo Z-F, Guo Z-H, Sinniah K, Witte AB, Coghi P, Monti D. 2012. Interaction between Plasmodium falciparum and Mycobacterium tuberculosis: a co-factor model for neurodegeneration induced by antimalarial drugs of the artemisinin type. Neurotoxicology 73:69–79. https://doi.org/10.1016/j.neuro.2019.07.005.
88. Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350–1359.
89. Steyn JD, Wiesner L, Du Plessis LH, Grobler AF, Smith PJ, Chan W-C, Haynes RK, Kotzé AF. 2011. Absorption of the novel artemisinin derivatives artemisone and artemiside: potential application of Pheroid™ technology. Int J Pharm 414:260–266. https://doi.org/10.1016/j.ijpharm.2011.05.003.
90. Gibbard L, Pravin K, Abay E, Wilhelm A, Swart K, Lawrence N, Khoury R, van der Westhuizen J, Smith P, Wiesner L. 2016. In vitro and in vivo pharmacokinetics of aminoalkylated diarylpropanes NP085 and NP102. Antimicrob Agents Chemother 60:3065–3069. https://doi.org/10.1128/AAC.02104-15.